Trinity Biotech plc Sponsored ADR
Trinity Biotech is a science and technology company with a well-established foundation in high-quality laboratory and point-of-care diagnostics, now repositioning to pursue opportunities in advanced measurement, analytical science, and data-driven systems as it helps bridge the p
Investor website: https://trinitybiotech.com/
About
Trinity Biotech is a science and technology company with a well-established foundation in high-quality laboratory and point-of-care diagnostics, now repositioning to pursue opportunities in advanced measurement, analytical science, and data-driven systems as it helps bridge the physical-to-digital gap in an increasingly AI-driven world. The company has developed and commercialized trusted diagnostic solutions built on deep expertise in assay development, biosensing, analytical chemistry, and regulated manufacturing. Its product portfolio includes FDA-cleared analyzers and rapid tests, reflecting long-standing capabilities in regulated assay and instrument development. The current innovation focus includes biosensors and mass spectrometry-based solutions, emphasizing precision, reproducibility, and data integrity. Trinity Biotech aims to deliver sustained value through participation in markets where precision measurement, system reliability, and data convergence are critical.
Verified company data
- Leadership
- Gary Keating PhD (Chief Technology Officer, Highly experienced technical leader in the IVD industry with expertise in team building, planning, and troubleshooting. Has held CTO and R&D roles, overseeing the development and launch of diagnostic products.), Matthew Wictome (Vice President of Quality and Regulatory Affairs, Founder and Managing Director of Datod Consulting with over 30 years of experience in healthcare. Holds multiple degrees in Biochemistry and Strategy, and co-author of a practical guide on transforming quality organizations.)
Verified data last updated:
Recent filings
- Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 · trib_2026-09-09_11-35-03.pdf
- Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 · trib_2026-09-08_20-00-17.pdf
- Notice of Effectiveness · trib_2026-09-02_03-15-17.pdf
- Post-Effective amendments for registration statement · trib_2026-08-28_19-17-50.pdf
- Amendment Withdrawal Request · trib_2026-08-27_19-39-24.pdf
- [Amend] Registration statement for certain foreign private issuers · trib_2026-08-21_17-27-32.pdf
- Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 · trib_2026-08-17_11-32-09.pdf
- Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 · trib_2026-08-14_13-08-49.pdf